- Home
- RQI vs KLTOW Comparison
RQI vs KLTOW Comparison
Compare RQI & KLTOW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RQI | KLTOW |
|---|---|---|
| Founded | 2002 | N/A |
| Country | United States | United States |
| Employees | N/A | 3 |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | N/A |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | RQI | KLTOW |
|---|---|---|
| Price | $11.61 | $0.12 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 432.6K | N/A |
| Earning Date | 01-01-0001 | N/A |
| Dividend Yield | ★ 8.20% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.17 | N/A |
| 52 Week High | $12.64 | N/A |
Technical Indicators
Market Signals| Indicator | RQI | KLTOW |
|---|---|---|
| Relative Strength Index (RSI) | 49.18 | 47.38 |
| Support Level | $11.41 | $0.10 |
| Resistance Level | $11.54 | $0.15 |
| Average True Range (ATR) | 0.12 | 0.02 |
| MACD | 0.03 | -0.00 |
| Stochastic Oscillator | 65.62 | 58.66 |
Price Performance
Historical ComparisonAbout RQI Cohen & Steers Quality Income Realty Fund Inc
COHEN & STEERS QUALITY INCOME REALTY FUND INC is a diversified, closed-end management investment company. The primary investment objective of the fund is high current income through investment in real estate securities. Its secondary objective is capital appreciation. The Fund invests at least its total assets in income-producing common stocks and other securities issued by real estate companies, such as real estate investment trusts under normal market conditions.
About KLTOW Klotho Neurosciences Inc. Warrant
Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.